How I avoided AstraZeneca share price crash

In Citywire Money, Ketan Patel, fund manager at EdenTree Investment Management, reflects on the failure of the Mystic drug trial that caused a 15.9% drop in AstraZeneca shares. He says that it doesn’t bode well as the Mystic treatment is scheduled for to reach peak sales in 2023.

Link

 

top